在患有隔离性夜间高血压的患者中,循环血管素-(1-7) 降低
Julián Minetto1,2, María B Cuello3, Fernando P Dominici3
1Hospital Interzonal General Agudos San Martín de La Plata.
Journal of hypertension
|May 1, 2024
概括
隔离性夜间高血压 (INHT) 与循环中的血管素 (Ang) (1-7) 和Ang II水平的降低有关. 这些氨酸- ангиотензин系统 (RAS) 变化可能有助于INHT的发展.
科学领域:
- 心血管科学 心血管科学
- 内分泌学 在内分泌学.
- 高血压研究 高血压研究
背景情况:
- 隔离性夜间高血压 (INHT),以夜间血压升高 (BP) 和白天血压正常为特征,是心血管发病率和死亡率的重要危险因素.
- 氨酸-血管素系统 (RAS) 在血压调节中起着至关重要的作用,其调节失调与各种高血压疾病有关.
研究的目的:
- 调查该假设,在循环氨酸-血管素系统 (RAS) 的变化有助于孤立夜间高血压 (INHT) 的发展.
- 为了检查血管新素 (Ang) (1-7),Ang II和ACE2活动的循环水平与INHT的存在之间的关联.
主要方法:
- 门诊血压监测 (ABPM) 用于诊断50名转诊血压评估的患者的INHT.
- 在26名被诊断患有INHT的患者中测量了Ang (1-7),Ang II和ACE2活动的循环水平,并与正常压力个体进行了比较.
- 使用统计分析,包括后勤回归来确定RAS组件与INHT之间的关联.
主要成果:
- 与正常血压患者相比,INHT患者年龄较大,体重指数 (BMI) 更高.
- 在INHT患者中观察到Ang (1-7) (P=0.002) 和Ang II (P=0.02) 的循环水平较低,而ACE2活性没有显著变化.
- 夜间透气血压 (DBP) 与Ang (1-7) 和Ang II水平显著相关.
结论:
- 该研究发现,在患有隔离性夜间高血压 (INHT) 的个体中,循环宁-血管素系统 (RAS) 组件存在显著差异.
- 较低的Ang (1-7) 和Ang II水平与INHT有关,这表明RAS失调在其发病过程中的潜在作用.
- 这些发现强调了在INHT及其相关心血管风险的背景下评估RAS的重要性.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
621
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
621
Antihypertensive Drugs: Direct Renin Inhibitors
606
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
606
Antihypertensive Drugs: Angiotensin II Receptor Blockers
716
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
716
Hormonal Regulation
33.1K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
59
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
59


